RP-L301
Phase 2Recruiting 0 watching 0 views this week⚡ Active
44
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pyruvate Kinase Deficiency
Conditions
Pyruvate Kinase Deficiency
Trial Timeline
Aug 1, 2024 → Jan 1, 2029
NCT ID
NCT06422351About RP-L301
RP-L301 is a phase 2 stage product being developed by Rocket Pharmaceuticals for Pyruvate Kinase Deficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06422351. Target conditions include Pyruvate Kinase Deficiency.
Hype Score Breakdown
Clinical
17
Activity
12
Company
2
Novelty
5
Community
5
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06422351 | Phase 2 | Recruiting |
| NCT04105166 | Phase 1 | Completed |
Competing Products
9 competing products in Pyruvate Kinase Deficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Triheptanoin | Ultragenyx Pharmaceutical | Phase 1 | 28 |
| Mitapivat + Mitapivat-matching placebo | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat + Mitapivat-matching placebo | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat | Agios Pharmaceuticals | Phase 3 | 72 |
| Placebo + AG-348 | Agios Pharmaceuticals | Phase 3 | 72 |
| Mitapivat | Agios Pharmaceuticals | Approved | 80 |
| AG-348 | Agios Pharmaceuticals | Phase 3 | 72 |
| AG-348 | Agios Pharmaceuticals | Phase 2 | 47 |
| RP-L301 | Rocket Pharmaceuticals | Phase 1 | 25 |